Filtered By:
Management: Funding
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 373 results found since Jan 2013.
NIH establishes new childhood asthma clinical research network
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $10 million in first-year funding to establish a clinical research network called Childhood Asthma in Urban Settings (CAUSE). This nationwide network will conduct observational studies and clinical trials to improve understanding of asthma and develop treatment and prevention approaches tailored to children of low-income families living in urban communities. NIAID intends to provide approximately $70 million over seven years to support the CAUSE network.
Source: EurekAlert! - Medicine and Health - April 23, 2021 Category: International Medicine & Public Health Source Type: news
UGA to establish national NIH-funded center to fight flu
(University of Georgia) The National Institutes of Health has awarded the University of Georgia a contract to establish the Center for Influenza Disease and Emergence Research (CIDER). The contract will provide $1 million in first-year funding and is expected to be supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, for seven years and up to approximately $92 million.
Source: EurekAlert! - Biology - April 15, 2021 Category: Biology Source Type: news
NIAID funds new influenza research network
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases has established a network of research sites to study the natural history, transmission and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks. The program, called the Centers of Excellence for Influenza Research and Response (CEIRR), is expected to be supported for seven years by NIAID contracts to five institutions. Funding for the first year of the contracts will total approximately $24 million.
Source: EurekAlert! - Infectious and Emerging Diseases - April 14, 2021 Category: Infectious Diseases Source Type: news
NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Spring 2021 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NICDR News
Science Advances
Grantee News
NIDCR News
NIDCR & NIH Stand Against Structural Racism
NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH initiative—called UNIT...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news
PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an *
In the Dragonfly:
*NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open
The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news
Group led by UCLA professor awarded $8.8 million for HIV intervention using mobile app
A team of researchers co-led byUCLA Fielding School of Public Health epidemiology professor Matthew Mimiaga has received an $8.8 million grant from the National Institute of Allergy and Infectious Diseases to conduct a nationwide study aimed at reducing the spread of HIV, the virus that causes AIDS, among young transgender women through the use of a mobile app.The app, LifeSkills Mobile, allows high-risk women who are unable to participate in face-to-face interventions due to geographic and socioeconomic barriers to easily access comprehensive HIV prevention information and strategies through their mobile devices. The fi...
Source: UCLA Newsroom: Health Sciences - March 10, 2021 Category: Universities & Medical Training Source Type: news
We May Never Eliminate COVID-19. But We Can Learn to Live With It
When does a pandemic end? Is it when life regains a semblance of normality?
Is it when the world reaches herd immunity, the benchmark at which enough people are immune to an infectious disease to stop its widespread circulation? Or is it when the disease is defeated, the last patient cured and the pathogen retired to the history books?
The last scenario, in the case of COVID-19, is likely a ways off, if it ever arrives. The virus has infected more than 100 million people worldwide and killed more than 2 million. New viral variants even more contagious than those that started the pandemic are spreading across the world. And...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cover Story COVID-19 feature Magazine Source Type: news
Biden ’s First Three Steps to Getting COVID-19 Vaccines to Every American
Less than a week after taking office, President Joe Biden announced three major steps to improve the country’s vaccination plans, and his Administration’s COVID-19 response team held its first press briefing.
On Jan. 26, the President outlined the first three steps his team will take as part of a National Action Strategy for responding to the pandemic. First, the Administration will increase minimum weekly shipments of vaccines to states to 10 million doses, from the current 8.6 million. Next, Biden guaranteed these shipment numbers for the next three weeks, which allows states to plan out for the next month ho...
Source: TIME: Health - January 27, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten
PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 -- (Heal... Biopharmaceuticals, Venture Capital Ukko, Bayer, food allergy
Source: HSMN NewsFeed - January 27, 2021 Category: Pharmaceuticals Source Type: news
mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!”
I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed.
This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news
The COVID-19 Virus Is Mutating. What Does That Mean for Vaccines?
As we enter the second year of living with the new coronavirus SARS-CoV-2, the virus is celebrating its invasion of the world’s population with yet more mutated forms that help it to spread more easily from person to person.
One, first detected in the U.K. in December, has already raised alarms about whether the COVID-19 virus is now escaping from the protection that vaccines just being rolled out now might provide. The variant has also been found in the U.S. Already, U.K. officials have tightened lockdowns in England, Scotland and Wales, and over the holidays, more than 40 countries banned travelers from the region ...
Source: TIME: Health - January 7, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Phase 3 trial of Novavax investigational COVID-19 vaccine opens
(NIH/National Institute of Allergy and Infectious Diseases) The Phase 3 trial of another investigational coronavirus disease 2019 (COVID-19) vaccine has begun enrolling adult volunteers. The randomized, placebo-controlled trial will enroll approximately 30,000 people at approximately 115 sites in the United States and Mexico. It will evaluate the safety and efficacy of NVX-CoV2373, a vaccine candidate developed by Novavax, Inc., of Gaithersburg, Maryland. Novavax is leading the trial as the regulatory sponsor. NIAID and BARDA are funding the trial.
Source: EurekAlert! - Infectious and Emerging Diseases - December 28, 2020 Category: Infectious Diseases Source Type: news
Top Global Health Moments of 2020
By The Editorial Team,
IntraHealth International
Community Health Nurse Olivia Yeboah thoroughly washes her hands at the Akropong Clinic in Ghana. Photo by Emmanuel Attramah, PMI Impact Malaria/US President ' s Malaria Initiative.December 17, 2020If we wanted to, we could list a COVID-19 moment for every month of 2020. We all know that the onset of the coronavirus pandemic—first in China and then worldwide—overwhelmed news coverage this year. And with good reason. It’s the first large-scale global pandemic in 100 years. At the time this article was pu...
Source: IntraHealth International - December 17, 2020 Category: International Medicine & Public Health Authors: kseaton Tags: HIV & AIDS COVID-19 Nutrition Policy Advocacy Health Workforce Systems Nursing Midwifery 2020 Health Workers Source Type: news
